More on TVTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-96.6% Growth)
- Ratings (8.0 Score)

Upcoming Events

- Earnings (10/26/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Travere Therapeutics (NQ:TVTX)
Delayed: 50.08 -2.35 (4.48%)
Prev. Close $52.43  
Open$52.00 
52 Wk High$ 
52 Wk Low$ 
Day High$52.22 
Day Low$49.78 
P/E N/A  
EPS$ 
Volume2,314,603 

Friends, Peers and Foes (?): CSL, CSLLY, LGND, ARWR, CELC (more...)

Oct 23, 2026 07:20 PM Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Oct 19, 2026 04:05 PM Form 4 Travere Therapeutics, For: Oct 15 Filed by: Dube Eric M
Oct 15, 2026 04:41 PM Form 144 Travere Therapeutics, Filed by: Dube Eric M
Oct 12, 2026 05:00 PM Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 10:00 AM Travere to present Filspari kidney disease data at ASN 2026
Oct 2, 2026 10:00 AM Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Sep 24, 2026 06:11 AM Travere Therapeutics (TVTX) PT Raised to $89 at Guggenheim
Sep 23, 2026 07:00 AM Travere gets patent allowance for Filspari use in kidney disease
Sep 23, 2026 07:00 AM Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental
Sep 21, 2026 04:11 PM Form 8-K Travere Therapeutics, For: Sep 21
View All Articles

Entities mentioned with TVTX

View All Entities